Xontogeny is a life sciences venture focused on accelerating the development of new therapies and technologies that address significant unmet medical needs. The company partners with academia, innovators, and biotech companies to support the advancement of novel therapeutics through preclinical development and into clinical trials.

Chris Garabedian

Xontogeny

Xontogeny (zon-TOJ-uh-nee) is a biotech aggregator with a differentiated business model to support the accelerated development of life science technologies in the pursuit of helping patients with serious diseases. Speciﬁcally, we partner with entrepreneurs, providing the leadership and operating experience needed to increase the probability of success with early drug and technology development.

At Xontogeny, we believe that scientific founders supply the passion and determination integral to the success of their companies. While the foundation of success is good science, how that science is developed from inception to maturity serves as the critical pathway. Therefore, we focus on supporting the entrepreneur’s pursuit and optimizing the development pathway with an exceptionally talented and experienced operational team. With our team’s track record of success, entrepreneurs of affiliated companies will gain the support and guidance they need while remaining lean, virtual, and without the financial burden of supporting a full-time team.

This dynamic model has the additional benefit of supporting the goals of the founding scientists and entrepreneurs to retain more control and equity, while increasing the chance of accessing investment, and ultimately development success.

Metric
Company Name	Xontogeny
Symbol
MSH ID	COM:XONTOGENY
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count	13
Website	xontogeny.com
LinkedIn	xontogeny
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:XONTOGENY

Xontogeny

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue